Search
Vinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalWhile these patients have a median survival of approximately 4 months and a poor prognosis [L1396], there is currently no standard therapy in patients with advanced urothelial carcinoma [A32626]. … Like other vinca agents, vinflunine is an anti-mitotic agent that induces a cell cycle arrest at the G2/M phase and promotes cell death via apoptosis [L1396].
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 20',20'-difluoro-3',4'-dihydrovinorelbine, 4'-deoxy-20',20'-difluoro-5'-norvincaleukoblastinePitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigationalPitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. … In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersTafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigational[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Categories: Heterocyclic Compounds, 2-RingSynonyms: 2-(3,5-Dichlorophenyl)benzoxazole-6-carboxylic acid, 6-BENZOXAZOLECARBOXYLIC ACID, 2-(3,5-DICHLOROPHENYL)-Afuresertib
go.drugbank.com/drugs/DB11648InvestigationalAfuresertib has been used in trials studying the treatment of Cancer and Neoplasms, Haematologic.
Categories: Heterocyclic Compounds, 1-RingBuparlisib
go.drugbank.com/drugs/DB11666InvestigationalBuparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.
Categories: Heterocyclic Compounds, 1-Ring, Phosphatidylinositol 3-Kinases, antagonists & inhibitorsPyridoxamine
go.drugbank.com/drugs/DB11673InvestigationalPyridoxamine has been used in trials studying the treatment of Kidney Stones.
Categories: Vitamin B Complex, Heterocyclic Compounds, 1-RingFruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalFruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. … The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingPacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalof both primary and secondary MF in patients with platelet counts < 50 x 10<sup>9</sup>/L. … [L40754] It provides a treatment option for patients who have MF with severe thrombocytopenia, which occurs in approximately one-third of MF patients and carries with it a particularly poor prognosis.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersSetmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[L24474] It is an agonist of the melanocortin 4 receptor. … [L24429] On May 4, 2023, it was approved by Health Canada.[L46327]
Categories: Melanocortin 4 Receptor Agonist, Melanocortin 4 Receptor AgonistsEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … [L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: BRAFTOVI® 75 MG CÁPSULAS